Stereoisomeric fused-cyclopropyl analogues of 4-hydroxycyclohexane carboxamides and related compounds

Stereoisomeric mitofusin activators with a cyclopropane ring adjacent to the amide carbonyl group address the limitations of existing mitofusin activators by enhancing plasma half-life and neurological bioavailability, effectively treating mitochondrial-associated diseases.

WO2026044165A1PCT designated stage Publication Date: 2026-02-26DORN II GERALD W
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
PCT/US2025/043077
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-08-22
Filing Date
2025-08-22
Publication Date
2026-02-26

AI Technical Summary

Technical Problem

Existing mitofusin activators, such as N-(trans-4-hydroxycyclohexyl)-6-phenylhexanamide, suffer from short plasma half-life and low neurological bioavailability, limiting their effectiveness in treating mitochondrial-associated diseases.

Method used

Development of stereoisomeric small-molecule compounds, particularly those with a cyclopropane ring fused adjacent to the amide carbonyl group, such as (R,R)-configured compounds, which enhance plasma half-life and neurological bioavailability.

Benefits of technology

The stereoisomeric compounds exhibit extended plasma half-life and greater neurological bioavailability, effectively promoting mitofusin activation and improving treatment outcomes for neurodegenerative diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2025043077_26022026_PF_FP_ABST
    Figure US2025043077_26022026_PF_FP_ABST
Patent Text Reader

Abstract

Compositions may comprise a mitofusin activator having a structure represented by Formula 4A or Formula 4B or a pharmaceutically acceptable salt, solvate, hydrate, or tautomer thereof. Formula 4A Formula 4B R1 is an optionally substituted aryl or heteroaryl group, such as phenyl. A mass ratio of the structure represented by Formula 4A to the structure represented by Formula 4B is about 60:40 or greater or about 40:60 or less, preferably 95:5 or greater or 5:95 or less. More preferably, the compositions comprise 95:5 or greater of the structure represented by Formula 4A. The compositions may be administered to a subject having a mitochondria-associated disease, disorder, or condition.
Need to check novelty before this filing date? Find Prior Art

Description

Atty. Docket No.: 076760-000051STEREOISOMERIC FUSED-CYCLOPROPYL ANALOGUES OF 4- HYDROXYCYCLOH EXANE CARBOXAMIDES AND RELATED COMPOUNDSSTATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

[0001] This invention was made with government support under grant NIDS R42NS115184 awarded by the National Institutes of Health. The government has certain rights in the invention.FIELD

[0002] The present disclosure generally relates to mitofusin activation, and more specifically, compositions comprising stereoisomeric small-molecule compounds effective to promote mitofusin activation.BACKGROUND

[0002] Mitochondrial dysfunction may contribute to various types of age-related neurodegenerative diseases and other neurodegenerative diseases, as well as to aging itself. Defective mitochondrial fusion or fission may be especially problematic in this regard, especially when imbalanced fusion and fission lead to mitochondrial fragmentation. Among the many age- related neurodegenerative diseases in which mitochondrial dysfunction has been implicated include, for example, Charcot-Marie-Tooth disease, amyotrophic lateral sclerosis (ALS), and Huntington's disease.

[0003] Mitochondrial fusion is initiated by outer mitochondrial membrane-embedded mitofusin (MFN) proteins whose extra-organelle domains extend across cytosolic space to interact with counterparts on neighboring mitochondria. The physically linked organelles create oligomers of varying sizes. Mitofusins subsequently induce outer mitochondrial membrane fusion mediated by catalytic GTPase. Aberrant mitofusin activity is believed to be a primary contributor to mitochondrial-based neurodegenerative diseases. For these reasons, mitofusins are attractive targets for drug discovery.

[0004] Several chemical entities have been found to target mitofusins, but most have failed to display idealized pharmacokineticAtty. Docket No.: 076760-000051 properties compatible with in vivo use. U.S. Patent 11,026,904 describes various N-(cycloalkyl or heterocycloalkyl) 6-phenylhexanamide compounds. 4- Hydroxycyclohexyl is a particularly effective substituted cycloalkyl in such mitofusin activators. U.S. Patent 11,083,699 describes trans-N-(4- hydroxycyclohexyl)-6-phenylhexanamide compounds. The corresponding cis- stereoisomer is inactive toward promoting mitofusin activation. N-(trans-4- hydroxycyclohexyl)-6-phenylhexanamide has a relatively short plasma half-life (ti / 2 = 1.1 hr in mouse plasma) and a brain / plasma partition coefficient of only about 10.1%. While useful for treating some conditions, the short plasma halflife and limited brain / plasma partition coefficient may make this compound ineffective for mitigating some types of mitochrondria-associated diseases. Fusion of a cyclopropyl group adjacent to the amide carbonyl group may improve the pharmacokinetic properties; however, the pharmacokinetic properties still have room for improvement.

[0005] Another related class of amide-based mitofusin activators is described in U.S. Patent Application Publication 2024 / 0050386, wherein the 4- hydroxycyclohexyl group is bonded directly to the amide carbonyl group and the amide nitrogen is moved to the other side of the amide carbonyl group. Such mitofusin activators may have improved pharmacokinetic properties in some instances compared to the corresponding 6-phenylhexanamides.BRIEF DESCRIPTION OF THE DRAWINGS

[0006] The following figures are included to illustrate certain aspects of the present disclosure, and should not be viewed as exclusive embodiments. The subject matter disclosed is capable of considerable modifications, alterations, combinations, and equivalents in form and function, as will occur to one having ordinary skill in the art and having the benefit of this disclosure.

[0007] FIG. 1 is a synthetic scheme for preparing a racemic mixture of compounds having structures represented by Formulas 4A and 4B (R1= phenyl).

[0008] FIG. 2 is a HPLC chromatogram showing the chiral separation of compounds having structures represented by Formulas 5A and 5B.

[0009] FIG. 3 is dose-response curve for compounds having structures represented by Formulas 5A and 5B.Atty. Docket No.: 076760-000051DETAILED DESCRIPTION

[0010] The present disclosure generally relates to mitofusin activation, and more specifically, compositions comprising stereoisomeric small-molecule compounds effective to promote mitofusin activation.

[0011] As discussed above, various 6-phenylhexanamide compounds are potent mitofusin activators. Optional substitution may be present upon the phenyl ring, or alternative aryl or heteroaryl groups may be present. N- trans- 4-hydroxycyclohexyl)-6-phenylhexanamide (Formula 1) is a representative example of such mitofusin activators. Although the pharmacokinetic properties of the compound having a structure represented by Formula 1 are acceptable for certain applications, its relatively short plasma half-life and low neurological bioavailability may limit the range of applications for which it might otherwise be applicable. By introducing rigidity into the methylene chain adjacent to the amide carbonyl group, such as by fusing the a- and - methylene groups into a cyclopropane ring (Formula 2), the plasma half-life and neurological bioavailability may be significantly improved; however, the pharmacokinetic properties still have room for improvement.The (R,R) configuration of the cyclopropane ring in Formula 2 (Formula 2A) is active toward promoting mitofusin activation, whereas the corresponding (S,S)Atty. Docket No.: 076760-000051 configuration of Formula 2 (structure not shown) is inactive. The corresponding (R,S) and (S,R) configurations were not investigated.Formula 2A

[0012] Structural analogues of Formula 1 having the amide nitrogen moved to the other side of the carbonyl group may maintain mitofusin activity in some cases. Again, optional substitution may be present upon the phenyl ring, or alternative aryl or heteroaryl groups may be present instead of the phenyl ring. 4-Hydroxy-N-(5-phenylpentyl)cyclohexane-l-carboxamide (Formula 3) is an example of such compounds.Formula 3Unlike the structural analogue represented by Formula 2A, fusion of the methylene groups into a cyclopropane ring adjacent to the amide nitrogen (Formula 3A) resulted in near-complete loss of mitofusion activity.Formula 3AAtty. Docket No.: 076760-000051

[0013] Surprisingly, as disclosed herein, the mitofusin activity of compounds having a structure analogous to Formula 3A may be restored by extending the methylene chain by one additional carbon atom. The structure represented by Formula 4 is an example of such mitofusin activators.Formula 4R1is an optionally substituted aryl or optionally substituted heteroaryl group, such as an optionally substituted phenyl group. Like the cyclopropane ring in Formula 3A, the cyclopropanation chemistry may produce a mixture of (R,R) and (S,S) cyclopropane stereoisomers (Formulas 4A and 4B, respectively). The analogues with R1= phenyl are shown as Formulas 5A and 5B.Formula 4BAtty. Docket No.: 076760-000051Formula 5B

[0014] Upon performing chiral separation of the two cyclopropane stereoisomers (or synthesizing each stereoisomer stereospecifically), it was unexpectedly discovered that one of the stereoisomers is very active toward promoting mitofusion activation (ECso = 623 pM), whereas the other stereoisomer is only a partial agonist with much lower activity (EC5o > 1 urn). Based on chiral syntheses, the more active stereoisomer has been determined to have an (R,R) configuration at the cyclopropane ring (Formula 5A). Advantageously, in addition to activating mitofusins, compounds having a structure represented by Formulas 4A and / or 4B, such as Formulas 5A and / or 5B, may exhibit extended plasma half-lives and much greater neurological bioavailability compared to their structural counterparts having the amide nitrogen atom located on the other side of the carbonyl group (e.g., structures such as those represented by Formula 1 or Formula 2).

[0015] Accordingly, the present disclosure provides compositions comprising a mitofusin activator or a pharmaceutically acceptable salt, solvate, hydrate, or tautomer thereof. The mitofusin activator may have a structure represented by Formula 4A or Formula 4B. In the compositions disclosed herein, the compound having the structure represented by Formula 4A or the compound having the structure represented by Formula 4B may be present inAtty. Docket No.: 076760-000051 a mass excess with respect to the other structure (z'.e., a stereoisomeric excess). In non-limiting examples, a mass ratio of the compound having the structure represented by Formula 4A to the compound having the structure represented by Formula 4B may be about 60:40 or greater or about 40:60 or less. Preferably, the compound having the structure represented by Formula 4A may be present in excess (e.g., at a mass ratio of 60:40 or greater) relative to the compound having the structure represented by Formula 4B.

[0016] Various optional substitutions may be present upon the phenyl group, or alternative aryl or heteroaryl groups may be present instead of a phenyl group.

[0017] When R1is a phenyl group, the phenyl group may be substituted or unsubstituted (Formulas 5A and 5B). Optional substitution(s) that may be present upon the phenyl group (or alternative aryl or heteroaryl groups) include one or more of the following entities: amine, alkylamine, amide, alkylamide, alkoxy, aryloxy, hydroxyalkyl, azo, halo (F, Cl, Br, I), Ci-8 alkyl, carbonyl, carboxylic acids or carboxylic esters, cyano, C3-8 cycloalkyl, C3-8 heteroaryl, C3-8 heterocyclyl, Ce-Cio aryl, hydroxy, thiol, thioether, sulfoxide, sulfone, and sulfonamide. The optional substitutions may be present at any available ring position. 0, 1, 2, 3, 4, or 5 optional substitutions may be present.

[0018] Other examples of R1may include aryl groups such as 1- naphthyl, 2-naphthyl, anthracenyl, phenanthrenyl, indenyl, and tetrahydronaphthyl. Suitable heteroaryl groups that may be present as R1include, for example, benzofuranyl, benzothienyl, indolyl, benzopyrazolyl, coumarinyl, isocoumarinyl, isoquinolinyl, pyrrolyl, pyrrolidinyl, thienyl, furanyl, thiazolyl, imidazolyl, pyrazolyl, triazolyl, quinolinyl, pyrimidinyl, pyridinyl, pyridonyl, pyrazinyl, pyridazinyl, oxazolyl, isothiazolyl, isoxazolyl, tetrazolyl, or any isomer thereof. Any of these aryl or heteroaryl groups may be optionally substituted with the groups further specified above.

[0019] When the stereogenic carbon atoms of the cyclopropane ring have an (R,R) or (S,S) configuration, the cyclopropane ring has a transstereochemistry. Advantageously, the trans-stereochemistry of the 4- hydroxycyclohexyl group and the trans-stereochemistry of the cyclopropane ring each may be independently established before assembling the mitofusinAtty. Docket No.: 076760-000051 activators together, as described further below. The cyclopropanation chemistry may lead exclusively to a trans-stereochemistry of the cyclopropane ring, with either one or both of the (R,R) or (S,S) configurations being produced, depending on the chosen synthesis method. In the compositions disclosed herein, either the (R,R) or (S,S) configuration may be produced preferentially or exclusively, or the (R,R) and the (S,S) configurations may be produced as a mixture of stereoisomers that are separated from one another to provide one stereoisomer in high isomeric purity relative to the other stereoisomer.

[0020] Compositions of the present disclosure may feature greater than a 1 : 1 mass ratio of one cyclopropane stereoisomer relative to the other cyclopropane stereoisomer. In some examples, the mass ratio of the structure represented by Formula 4A to the structure represented by Formula 4B (or vice versa) may be about 60% or greater, or about 70% or greater, or about 80% or greater, or about 90% or greater, or about 95% or greater, or about 97% or greater, or about 99% or greater, or about 99.5% or greater, or about 99.9% or greater. Accordingly, in various examples, the mass ratio of the structure represented by Formula 4A to the structure represented by Formula 4B may be about 60:40 or greater or about 40:60 or less, or about 70:30 or greater or about 30:70 or less, or about 80:20 or greater or about 20:80 or less, or about 85: 15 or greater or about 15:85 or less, or about 90: 10 or greater or about 10:90 or less, or about 95: 5 or greater or about 5:95 or less, or about 98:2 or greater or about 2:98 or less, or about 99: 1 or greater or about 1 :99 or less, or about 99.9:0.1 or greater or about 0.1 :99.9 or less. In some examples, the mitofusin activators may consist essentially of one of the (R,R) configuration (Formula 4A) or the (S,S) configuration (Formula 4B).

[0021] Preferably, the mitofusin activator having a structure represented by Formula 4A may be present in excess to the mitofusin activator having a structure represented by Formula 4B. That is, the (R,R) cyclopropane stereoisomer may be present in excess to the (S,S) cyclopropane stereoisomer. Accordingly, in preferred examples, the mass ratio of the structure represented by Formula 4A to the structure represented by Formula 4B may be about 60:40 or greater, or about 70:30 or greater, or about 80:20 or greater, or about 85: 15 or greater, or about 90: 10 or greater, or about 95:5 or greater, or aboutAtty. Docket No.: 076760-00005198:2 or greater, or about 99: 1 or greater, or about 99.9:0.1 or greater. In some examples, the mitofusin activator in the compositions of the present disclosure may consist essentially of the mitofusin activator having a structure represented by Formula 4A. In any of the foregoing, R1may be phenyl or optionally substituted phenyl.

[0022] As used herein, the term "pharmaceutically acceptable salt" refers to organic or inorganic salts of a compound of the present disclosure that have specified toxicity and / or biodistribution properties. Suitable salts include, but are not limited, to sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, isonicotinate, lactate, salicylate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, and / or pamoate (z'.e., l,l'-methylene-bis-(2-hydroxy-3-naphthoate)) salts. The pharmaceutically acceptable salt may balance charge on the parent compound by being present as a counterion. More than one counterion may be present. When multiple counterions are present, the compounds may be present as a mixed pharmaceutically acceptable salt.

[0023] Pharmaceutically acceptable salts, solvates, and / or hydrates of the mitofusin activators may also be present in the compositions of the present disclosure. As used herein, the term "pharmaceutically acceptable solvate" refers to an association between one or more solvent molecules and a mitofusin activator of the present disclosure or a salt thereof, wherein the solvate has specified toxicity and / or biodistribution properties. Examples of solvents that may form pharmaceutically acceptable solvates include, but are not limited to, water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, and / or ethanolamine. As used herein, the term "pharmaceutically acceptable hydrate" refers to a mitofusin activator of the present disclosure or a salt thereof that further includes a stoichiometric or non-stoichiometric amount of water bound by non-covalent intermolecular forces, wherein the hydrate has specified toxicity and / or biodistribution properties.

[0024] The mitofusin activators described herein may be formulated using one or more pharmaceutically acceptable excipients (carriers) known toAtty. Docket No.: 076760-000051 persons having ordinary skill in the art. The term "pharmaceutically acceptable excipient," as used herein, refers to substances or components that do not cause unacceptable losses of pharmacological activity or unacceptable adverse side effects when administered to a subject. Example "pharmaceutically acceptable excipients" include, but are not limited to, solvents, dispersion media, coatings, disintegrants, antibacterial agents, antifungal agents, isotonic, and absorption delaying agents, provided that any of these agents do not produce significant side effects or are incompatible with the mitofusin activator in the composition. Example excipients are described, for example, in Remington's Pharmaceutical Sciences (A.R. Gennaro, Ed.), 21st edition, ISBN: 0781746736 (2005) and United States Pharmacopeia (USP 29) and National Formulary (NF 24), United States Pharmacopeial Convention, Inc, Rockville, Maryland, 2005 ("USP / NF"), or a more recent edition, and the components listed in the continuously updated Inactive Ingredient Search online database of the FDA. Other useful components that are not described in the USP / NF may also be used. Such formulations may contain a therapeutically effective amount of one or more mitofusin activators, optionally as a salt, tautomer, hydrate, and / or solvate, together with a suitable amount of excipient to provide a form for proper administration to a subject.

[0025] Compositions of the present disclosure may be stable to specified storage conditions. A "stable" composition refers to a composition having sufficient stability to allow storage at a convenient temperature, such as from about 0°C to about 60°C or about -20°C to about 50°C, for a commercially reasonable period of time, such as at least about one day, at least about one week, at least about one month, at least about three months, at least about six months, at least about one year, or at least about two years.

[0026] Compositions of the present disclosure may be tailored to suit one or more desired modes of administration, which may include, but are not limited to, parenteral, pulmonary, oral, topical, transdermal, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, ophthalmic, pulmonary, epidural, buccal, vaginal, and rectal. The compositions may also be administered in combination with one or more additional agents or together with other biologically active or biologically inert agents.Atty. Docket No.: 076760-000051

[0027] Controlled-release (or sustained-release) compositions may be formulated to extend the activity of the mitofusin activators and reduce dosing frequency. Controlled-release compositions may also be used to affect the time to onset of action or other characteristics, such as plasma levels of the mitofusin activator, and consequently affect the occurrence of side effects. Controlled-release compositions may be designed to initially release an amount of one or more mitofusin activators that produces the desired therapeutic effect, and gradually and continually release other amounts of the mitofusin activator to maintain the level of therapeutic effect over an extended period. In order to maintain a near-constant level of mitofusin activator in the body, the mitofusin activator may be released at a rate sufficient to replace the amount being metabolized or excreted from a subject. Alternately, the level of mitofusin activator in the body may fluctuate depending on the metabolic characteristics thereof. The controlled-release feature may be stimulated by various inducers (e.g., change in pH, change in temperature, enzymes, water, or other physiological conditions or molecules).

[0028] Agents or compositions described herein may also be used in combination with other therapeutic modalities, as described further below. Thus, in addition to the therapies described herein, one may also provide to the subject other therapies known to be efficacious for treatment of a disease, disorder, or condition being targeted by the mitofusin activator or a related disease, disorder, or condition.

[0029] Mitofusin activators of the present disclosure may stimulate mitochondrial fusion, increase mitochondrial fitness, and enhance mitochondrial subcellular transport. Accordingly, in another aspect of the present disclosure, any one or a combination of mitofusin activators of the present disclosure or a pharmaceutically acceptable salt, tautomer, hydrate, and / or solvate thereof may be administered in a therapeutically effective amount to a subject having or suspected of having a mitochondria-associated disease, disorder or condition. The subject may be a human or other mammal having or suspected of having a mitochondria-associated disease, disorder or condition.

[0030] The mitochondria-associated disease, disorder or condition may be a pheripheral nervous system (PNS) or central nervous system (CNS)Atty. Docket No.: 076760-000051 genetic or non-genetic disorder, physical damage, and / or chemical injury. In some aspects, in the method of treating a disease, disorder or condition for which a mitofusin activator is indicated, the PNS or CNS disorder may be selected from any one or a combination of: a chronic neurodegenerative condition wherein mitochondrial fusion, fitness, or trafficking are impaired; a disease or disorder associated with mitofusin-1 (MFN1) or mitofusin-2 (MFN2) dysfunction; a disease associated with mitochondrial fragmentation, dysfunction, or dysmotility; a degenerative neuromuscular condition such as Charcot-Marie-Tooth disease, amyotrophic lateral sclerosis (ALS), Huntington's disease, Alzheimer's disease, Parkinson's disease, hereditary motor and sensory neuropathy, autism, autosomal dominant optic atrophy (ADOA), muscular dystrophy, Lou Gehrig's disease, cancer, mitochondrial myopathy, diabetes mellitus and deafness (DAD), Leber's hereditary optic neuropathy (LHON), Leigh syndrome, subacute sclerosing encephalopathy, neuropathy, ataxia, retinitis pigmentosa, and ptosis (NARP), myoneurogenic gastrointestinal encephalopathy (MNGIE), myoclonic epilepsy with ragged red fibers (MERRF), mitochondrial myopathy, encephalomyopathy, lactic acidosis, stroke-like symptoms (MELAS), mtDNA depletion, mitochondrial neurogastrointestinal encephalomyopathy (MNGIE), dysautonomic mitochondrial myopathy, mitochondrial channelopathy, or pyruvate dehydrogenase complex deficiency (PDCD / PDH), diabetic neuropathy, chemotherapy-induced peripheral neuropathy, crush injury, SCI, traumatic brain injury (TBI), stroke, optic nerve injury, and / or related conditions that involve axonal disconnection.

[0031] Other mitochondria-associated diseases, disorders, or conditions that may be treated with the compositions disclosed herein, but are not limited to, Alzheimer's disease, ALS, Alexander disease, Alpers' disease, Alpers-Huttenlocher syndrome, alpha-methylacyl-CoA racemase deficiency, Andermann syndrome, Arts syndrome, ataxia neuropathy spectrum, ataxia (e.g., with oculomotor apraxia, autosomal dominant cerebellar ataxia, deafness, and narcolepsy), autosomal recessive spastic ataxia of Charlevoix- Saguenay, Batten disease, beta-propeller protein-associated neurodegeneration, cerebro-oculo-facio-skeletal syndrome (COFS), corticobasal degeneration, CLN1 disease, CLN10 disease, CLN2 disease, CLN3Atty. Docket No.: 076760-000051 disease, CLN4 disease, CLN6 disease, CLN7 disease, CLN8 disease, cognitive dysfunction, congenital insensitivity to pain with anhidrosis, dementia, familial encephalopathy with neuroserpin inclusion bodies, familial British dementia, familial Danish dementia, fatty acid hydroxylase-associated neurodegeneration, Friedreich's Ataxia, Gerstmann-Straussler-Scheinker Disease, GM2-gangliosidosis (e.g., AB variant), HMSN type 7 (e.g., with retinitis pigmentosa), Huntington's disease, infantile neuroaxonal dystrophy, infantile-onset ascending hereditary spastic paralysis, infantile-onset spinocerebellar ataxia, juvenile primary lateral sclerosis, Kennedy's disease, Kuru, Leigh's Disease, Marinesco-Sjbgren syndrome, mild cognitive impairment (MCI), mitochondrial membrane protein-associated neurodegeneration, motor neuron disease, monomelic amyotrophy, motor neuron diseases (MND), multiple system atrophy, multiple system atrophy with orthostatic hypotension (Shy-Drager Syndrome), multiple sclerosis, multiple system atrophy, neurodegeneration in Down's syndrome (NDS), neurodegeneration of aging, neurodegeneration with brain iron accumulation, neuromyelitis optica, pantothenate kinase-associated neurodegeneration, opsoclonus myoclonus, prion disease, progressive multifocal leukoencephalopathy, Parkinson's disease, Parkinson's disease-related disorders, polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy, prion disease, progressive external ophthalmoplegia, riboflavin transporter deficiency neuronopathy, Sandhoff disease, spinal muscular atrophy (SMA), spinocerebellar ataxia (SCA), striatonigral degeneration, transmissible spongiform encephalopathies (prion diseases), and / or Wallerian-like degeneration.

[0032] Still other mitochrondria-associated diseases, disorders, or conditions that may be treated with the compositions disclosed herein include abulia; agraphia; alcoholism; alexia; alien hand syndrome; Allan-Herndon- Dudley syndrome; alternating hemiplegia of childhood; Alzheimer's disease; amaurosis fugax; amnesia; ALS; aneurysm; angelman syndrome; anosognosia; aphasia; apraxia; arachnoiditis; Arnold-Chiari malformation; asomatognosia; Asperger syndrome; ataxia; attention deficit hyperactivity disorder; atr-16 syndrome; auditory processing disorder; autism spectrum; Behcets disease; bipolar disorder; Bell's palsy; brachial plexus injury; brainAtty. Docket No.: 076760-000051 damage; brain injury; brain tumor; Brody myopathy; Canavan disease; capgras delusion; carpal tunnel syndrome; causalgia; central pain syndrome; central pontine myelinolysis; centronuclear myopathy; cephalic disorder; cerebral aneurysm; cerebral arteriosclerosis; cerebral atrophy; cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL); cerebral dysgenesis-neuropathy- ichthyosis-keratoderma syndrome (CEDNIK syndrome); cerebral gigantism; cerebral palsy; cerebral vasculitis; cervical spinal stenosis; Charcot-Marie- Tooth disease; chiari malformation; chorea; chronic fatigue syndrome; chronic inflammatory demyelinating polyneuropathy (CIDP); chronic pain; Cockayne syndrome; Coffin-Lowry syndrome; coma; complex regional pain syndrome; compression neuropathy; congenital facial diplegia; corticobasal degeneration; cranial arteritis; craniosynostosis; Creutzfeldt-Jakob disease; cumulative trauma disorders; Cushing's syndrome; cyclothymic disorder; cyclic vomiting syndrome (CVS); cytomegalic inclusion body disease (CIBD); cytomegalovirus infection; Dandy-Walker syndrome; Dawson disease; de Morsier's syndrome; Dejerine-Klumpke palsy; Dejerine-Sottas disease; delayed sleep phase syndrome; dementia; dermatomyositis; developmental coordination disorder; diabetic neuropathy; diffuse sclerosis; diplopia; disorders of consciousness; down syndrome; Dravet syndrome; Duchenne muscular dystrophy; dysarthria; dysautonomia; dyscalculia; dysgraphia; dyskinesia; dyslexia; dystonia; empty sella syndrome; encephalitis; encephalocele; encephalotrigeminal angiomatosis; encopresis; enuresis; epilepsy; epilepsy-intellectual disability in females; Erb's palsy; erythromelalgia; essential tremor; exploding head syndrome; Fabry's disease; Fahr's syndrome; fainting; familial spastic paralysis; febrile seizures; Fisher syndrome; Friedreich's ataxia; fibromyalgia; Foville's syndrome; fetal alcohol syndrome; fragile x syndrome; fragile x- associated tremor / ataxia syndrome (FXTAS); Gaucher's disease; generalized epilepsy with febrile seizures plus; Gerstmann's syndrome; giant cell arteritis; giant cell inclusion disease; globoid cell leukodystrophy; gray matter heterotopia; Guillain-Barre syndrome; generalized anxiety disorder; HTLV-1 associated myelopathy; Hallervorden-Spatz syndrome; head injury; headache; hemifacial spasm; hereditary spastic paraplegia; heredopathia atactica polyneuritiformis; herpes zoster oticus; herpes zoster; HirayamaAtty. Docket No.: 076760-000051 syndrome; Hirschsprung's disease; Holmes-Adie syndrome; holoprosencephaly; Huntington's disease; hydranencephaly; hydrocephalus; hypercortisolism; hypoxia; immune-mediated encephalomyelitis; inclusion body myositis; incontinentia pigmenti; infantile refsum disease; infantile spasms; inflammatory myopathy; intracranial cyst; intracranial hypertension; isodicentric 15; Joubert syndrome; Karak syndrome; Kearns-Sayre syndrome; Kinsbourne syndrome; Kleine-Levin syndrome; Klippel Feil syndrome; Krabbe disease; Kufor-Rakeb syndrome; Lafora disease; Lambert-Eaton myasthenic syndrome; Landau-Kleffner syndrome; lateral medullary (Wallenberg) syndrome; learning disabilities; Leigh's disease; Lennox-Gastaut syndrome; Lesch-Nyhan syndrome; leukodystrophy; leukoencephalopathy with vanishing white matter; lewy body dementia; lissencephaly; locked-in syndrome; Lou Gehrig's disease (amyotrophic lateral sclerosis (ALS)); lumbar disc disease; lumbar spinal stenosis; Lyme disease - neurological sequelae; Machado- Joseph disease (spinocerebellar ataxia type 3); macrencephaly; macropsia; mal de debarquement; megalencephalic leukoencephalopathy with subcortical cysts; megalencephaly; Melkersson-Rosenthal syndrome; menieres disease; meningitis; Menkes disease; metachromatic leukodystrophy; microcephaly; micropsia; migraine; Miller Fisher syndrome; mini-stroke (transient ischemic attack); misophonia; mitochondrial myopathy; mobius syndrome; monomelic amyotrophy; Morvan syndrome; motor neuron disease - see ALS; motor skills disorder; Moyamoya disease; mucopolysaccharidoses; multi-infarct dementia; multifocal motor neuropathy; multiple sclerosis; multiple system atrophy; muscular dystrophy; myalgic encephalomyelitis; myasthenia gravis; myelinoclastic diffuse sclerosis; myoclonic encephalopathy of infants; myoclonus; myopathy; myotubular myopathy; myotonia congenita; narcolepsy; neuro-Behget's disease; neurofibromatosis; neuroleptic malignant syndrome; neurological manifestations of aids; neurological sequelae of lupus; neuromyotonia; neuronal ceroid lipofuscinosis; neuronal migration disorders; neuropathy; neurosis; Niemann-Pick disease; non-24-hour sleep-wake disorder; nonverbal learning disorder; O'Sullivan-McLeod syndrome; occipital neuralgia; occult spinal dysraphism sequence; Ohtahara syndrome; olivopontocerebellar atrophy; opsoclonus myoclonus syndrome; optic neuritis; orthostatic hypotension; otosclerosis; overuse syndrome; palinopsia;Atty. Docket No.: 076760-000051 paresthesia; Parkinson's disease; paramyotonia congenita; paraneoplastic diseases; paroxysmal attacks; Parry-Romberg syndrome; pediatric autoimmune neuropsychiatric disorders associated with streptococcoal infections (PANDAS); Pelizaeus-Merzbacher disease; periodic paralyses; peripheral neuropathy; pervasive developmental disorders; phantom limb / phantom pain; photic sneeze reflex; phytanic acid storage disease; Pick's disease; pinched nerve; pituitary tumors; pmg; polyneuropathy; polio; polymicrogyria; polymyositis; porencephaly; post-polio syndrome; postherpetic neuralgia (phn); postural hypotension; Prader-Willi syndrome; primary lateral sclerosis; prion diseases; progressive hemifacial atrophy; progressive multifocal leukoencephalopathy; progressive supranuclear palsy; prosopagnosia; pseudotumor cerebri; quadrantanopia; quadriplegia; rabies; radiculopathy; Ramsay Hunt syndrome type 1; Ramsay Hunt syndrome type 2; Ramsay Hunt syndrome type 3; Rasmussen encephalitis; reflex neurovascular dystrophy; refsum disease; REM sleep behavior disorder; repetitive stress injury; restless legs syndrome; retrovirus-associated myelopathy; Rett syndrome; Reye's syndrome; rhythmic movement disorder; Romberg syndrome; Saint Vitus' dance; Sandhoff disease; Schilder's disease (two distinct conditions); schizencephaly; sensory processing disorder; septo- optic dysplasia; shaken baby syndrome; shingles; Shy-Drager syndrome; Sjogren's syndrome; sleep apnea; sleeping sickness; snatiation; Sotos syndrome; spasticity; spina bifida; spinal cord injury; spinal cord tumors; spinal muscular atrophy; spinal and bulbar muscular atrophy; spinocerebellar ataxia; split-brain; Steele-Richardson-Olszewski syndrome; stiff-person syndrome; stroke; Sturge-Weber syndrome; stuttering; subacute sclerosing panencephalitis; subcortical arteriosclerotic encephalopathy; superficial siderosis; Sydenham's chorea; syncope; synesthesia; syringomyelia; tarsal tunnel syndrome; tardive dyskinesia; tardive dysphrenia; Tarlov cyst; Tay- Sachs disease; temporal arteritis; temporal lobe epilepsy; tetanus; tethered spinal cord syndrome; Thomsen disease; thoracic outlet syndrome; tic douloureux; Todd's Paralysis; Tourette syndrome; toxic encephalopathy; transient ischemic attack; transmissible spongiform encephalopathies; transverse myelitis; traumatic brain injury; tremor; trichotillomania; trigeminal neuralgia; tropical spastic paraparesis; trypanosomiasis; tuberousAtty. Docket No.: 076760-000051 sclerosis; 22ql3 deletion syndrome; Unverricht-Lundborg disease; vestibular schwannoma (acoustic neuroma); Von Hippel-Lindau disease (VHL); Viliuisk encephalomyelitis (VE); Wallenberg's syndrome; West syndrome; whiplash; Williams syndrome; Wilson's disease; y-linked hearing impairment; Zellweger syndrome; and / or age-induced sarcopenia or sarcopenia obesity.

[0033] Each of the states, diseases, disorders, and conditions, described herein, as well as others, may benefit from compositions and methods described herein. Generally, treating a state, disease, disorder, or condition includes preventing or delaying the appearance of clinical symptoms in a mammal that may be afflicted with or predisposed to the state, disease, disorder, or condition but does not yet experience or display clinical or subclinical symptoms thereof. Treating may also include inhibiting the state, disease, disorder, or condition (e.g., arresting or reducing the development of the disease or at least one clinical or subclinical symptom thereof). Furthermore, treating may include relieving the disease (e.g., causing regression of the state, disease, disorder, or condition or at least one of its clinical or subclinical symptoms). A benefit to a subject to be treated may be either statistically significant or at least perceptible to the subject or to a physician.

[0034] A mitochondria-associated disease, disorder, or condition may be a disease primarily caused by or secondarily associated with mitochondrial dysfunction, fragmentation, or loss-of-fusion, or associated with dysfunction in MFN1 or MFN2 catalytic activity or conformational unfolding. Mitochondrial dysfunction may be caused by genetic mutations of mitofusins or other (nuclear or mitochondrial encoded) genes, or may be caused by physical, chemical, or environmental injury to the CNS or PNS. Age-related decreases in mitochondrial activity may also be addressed through administration of the compositions of the present disclosure.

[0035] In a particular example, cancer chemotherapy-induced sensory and motor neuropathies may be prevented or treated with the compositions of the present disclosure. Chemotherapy-induced peripheral neuropathy is one of the most common complications of cancer chemotherapy, affecting 20% of all patients and almost 100% of patients receiving high doses of chemotherapeutic agents. Dose-dependent neurotoxicity of motor andAtty. Docket No.: 076760-000051 sensory neurons can lead to chronic pain, hypersensitivity to hot, cold, and mechanical stimuli, and / or impaired neuromuscular control. The most common chemotherapeutic agents linked to CIPN are platinum, vinca alkaloids, taxanes, epothilones, and the targeted proteasome inhibitor, bortezomib.

[0036] CIPN most commonly affects peripheral sensory neurons whose cell bodies are located in dorsal root ganglia lacking the blood-brain barrier that protects other components of the central and peripheral nervous system. Unprotected dorsal root ganglion neurons are more sensitive to neuronal hyperexcitability and innate immune system activation evoked by circulating cytotoxic chemotherapeutic agents. CIPN affects quality of life, and is potentially disabling, because it provokes chronic neuropathic pain that, like other causes of neuralgia (e.g., post herpetic neuralgia, diabetic mononeuropathy), is refractory to analgesic therapy. Motor nerve involvement commonly manifests as loss of fine motor function with deterioration in hand writing, difficulty in buttoning clothes or sewing, and sometimes upper and lower extremity weakness or loss of endurance. CIPN typically manifests within weeks of chemotherapy and in many cases improves after chemotherapy treatment ends, although residual pain, sensory, or motor defects are observed in one-third to one-half of affected patients. Unfortunately, CIPN-limited chemotherapy dosing can lead to delays, reduction, or interruption of cancer treatment, thus shortening survival.

[0037] Mitochondrial dysfunction and oxidative stress are implicated in CIPN because of observed ultrastructural morphological abnormalities, impaired mitochondria DNA transcription and replication, induction of mitochondrial apoptosis pathways, and reduction of experimental CIPN signs by anticipatory mitochondrial protection. Mitofusin activators may enhance overall mitochondrial function in damaged neurons, increase mitochondrial transport to areas of neuronal damage, and accelerate in vitro neuron repair / regeneration after chemotherapy-induced damage. For this reason, it is believed that mitofusin activators may reduce neuronal injury conferred by chemotherapeutic agents in CIPN and accelerate regeneration / repair of nerves damaged by chemotherapeutic anticancer agents. As such, the present disclosure provides for compositions and methods to treat cancer chemotherapy induced nerve injury and neuropathy.Atty. Docket No.: 076760-000051

[0038] In another example, injury in the CNS or PNS (e.g., trauma to the CNS or PNS, crush injury, SCI, TBI, stroke, optic nerve injury, or related conditions that involve axonal disconnection) may be treated with the compositions of the present disclosure. The CNS includes the brain and the spinal cord and the PNS is composed of cranial, spinal, and autonomic nerves that connect to the CNS.

[0039] Damage to the nervous system caused by mechanical, thermal, chemical, or ischemic factors may impair various nervous system functions such as memory, cognition, language, and voluntary movement. Most often, this is through accidental crush or transection of nerve tracts, or as an unintended consequence of medical interventions, that interrupt normal communications between nerve cell bodies and their targets. Other types of injuries may include disruption of the interrelations between neurons and their supporting cells or the destruction of the blood-brain barrier.

[0040] Mitofusin activators may rapidly reverse mitochondrial dysmotility in neurons from mice or patients with various genetic or chemotherapeutic neurodegenerative diseases, in axons injured by chemotherapeutic agents, and in axons severed by physical injury. For this reason, mitofusin activators may enhance regeneration / repair of physically damaged nerves, such as in vehicular and sports injuries, penetration trauma from military or criminal actions, and iatrogenic injury during invasive medical procedures. As such, the present disclosure provides for compositions and methods that may treat physical nerve injury.

[0041] Mitochondrial motility is also implicated in neuropathy and traumatic crush or severance nerve injuries. After nerve laceration or crush injury, nerves will either regenerate and restore neuromuscular function or fail to regenerate such that neuromuscular function in permanently impaired. Mitofusin activators may increase mitochondrial trafficking, thereby enabling a nerve to regenerate after traumatic injuries.

[0042] The amount of a mitofusin activator and excipient to produce a composition in a given dosage form may vary depending upon the subject being treated, the condition being treated, and the particular mode of administration. It will be appreciated that the unit content of mitofusin activator contained in an individual dose of a given dosage form need not inAtty. Docket No.: 076760-000051 itself constitute a therapeutically effective amount, as the necessary therapeutically effective amount could be reached by administration of a number of individual doses, or the therapeutic effect may be cumulative over time.

[0043] Dosing of the mitofusin activators of the present disclosure may occur as a single event or over a time course of treatment. For example, a mitofusin activator may be administered daily, weekly, bi-weekly, or monthly. For treatment of acute conditions, the time course of treatment may be at least several days, with dosing taking place at least once a day or continuously. Certain conditions could extend treatment from several days to several weeks. For example, treatment could extend over one week, two weeks, or three weeks. For chronic conditions, treatment could extend from several weeks to several months or even years.

[0044] Toxicity and therapeutic efficacy of the compositions described herein may be determined by standard pharmaceutical procedures in cell cultures or experimental animals for determining the LD5o (the dose lethal to 50% of the population) and the ED5o, (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index that may be expressed as the ratio LD50 / ED50, where larger therapeutic indices are generally understood in the art to be optimal.

[0045] Also provided herein are kits. Such kits may include an agent or composition described herein and, in certain aspects, instructions for administration. Such kits may facilitate performance of the methods described herein. When supplied as a kit, the different components of the composition may be packaged in separate containers and admixed immediately before use, or the components may be packaged together. Packaging of components may include a pack or dispenser device, which may contain one or more unit dosage forms containing the composition. The pack may, for example, comprise metal or plastic foil such as a blister pack. Such packaging of the components separately may also, in certain instances, permit long-term storage without losing activity of the components.

[0046] Kits may also include components in separate containers (e.g., sterile water or saline) to be added to a lyophilized active component packaged separately. For example, sealed glass ampules may contain a lyophilizedAtty. Docket No.: 076760-000051 component and in a separate ampule, sterile water, sterile saline, or other sterile vehicle, which may be packaged under a neutral non-reacting gas, such as nitrogen. Ampules may consist of any suitable material, such as glass, organic polymers, such as polycarbonate, polystyrene, ceramic, metal or any other material typically employed to hold a specified component. Other examples of suitable containers include bottles that may be fabricated from similar substances as ampules, and envelopes that may consist of foil-lined interiors, such as aluminum or an alloy. Other containers include test tubes, vials, flasks, bottles, syringes, and the like. Containers may have a sterile access port, such as a bottle having a stopper that may be pierced by a hypodermic injection needle. Other containers may have two compartments that are separated by a readily removable membrane that upon removal permits the components to mix. Removable membranes may be glass, plastic, rubber, and the like.

[0047] Embodiments disclosed herein include:

[0048] Embodiment 1. A composition comprising: a mitofusin activator having a structure represented by Formula 4A or Formula 4BFormula 4AAtty. Docket No.: 076760-000051Formula 4B or a pharmaceutically acceptable salt, solvate, hydrate, or tautomer thereof; wherein R1is an optionally substituted aryl or heteroaryl group, and a mass ratio of the structure represented by Formula 4A to the structure represented by Formula 4B is about 60:40 or greater or about 40:60 or less.

[0049] Embodiment 2. The composition of Embodiment 1, wherein R1is optionally substituted phenyl.

[0050] Embodiment 3. The composition of Embodiment 1, wherein R1is phenyl.

[0051] Embodiment 4. The composition of any one of Embodiments 1-3, further comprising: a pharmaceutically acceptable excipient.

[0052] Embodiment 5. The composition of Embodiment 1, wherein the mass ratio of the structure represented by Formula 4A to the structure represented by Formula 4B is about 95:5 or greater or about 5:95 or less.

[0053] Embodiment 6. The composition of Embodiment 5, wherein R1is optionally substituted phenyl.

[0054] Embodiment 7. The composition of Embodiment 5, wherein R1is phenyl.

[0055] Embodiment 8. The composition of any one of Embodiments 5-7, further comprising: a pharmaceutically acceptable excipient.

[0056] Embodiment 9. The composition of any one of Embodiments 5-8, wherein the mitofusin activator consists of the structure represented by Formula 4A or the structure represented by Formula 4B.

[0057] Embodiment 10. A method comprising: administering a therapeutically effective amount of theAtty. Docket No.: 076760-000051 composition of Embodiment 1 to a subject having or suspected of having a mitochondria-associated disease, disorder, or condition.

[0058] Embodiment 11. The method of Embodiment 10, wherein R1is optionally substituted phenyl.

[0059] Embodiment 12. The method of Embodiment 10, wherein R1is phenyl.

[0060] Embodiment 13. The method of any one of any one of Embodiments 10-12, wherein the mass ratio of the structure represented by Formula 4A to the structure represented by Formula 4B is about 95: 5 or greater or about 5:95 or less.

[0061] Embodiment 14. The method of Embodiment 13, wherein R1is optionally substituted phenyl.

[0062] Embodiment 15. The method of Embodiment 13, wherein R1is phenyl.

[0063] Embodiment 16. The method of any one of Embodiments 13-15, wherein the mitofusin activator consists of the structure represented by Formula 4A or the structure represented by Formula 4B.

[0064] Embodiment 17. The method of any one of Embodiments 10-16, wherein the mitochondria-associated disease, disorder or condition is a peripheral nervous system (PNS) or central nervous system (CNS) genetic or non-genetic disorder, physical damage, and / or chemical injury.

[0065] Embodiment 18. The method of any one of Embodiments 10-17, wherein the PNS or CNS disorder is one or more conditions selected from the group consisting of a chronic neurodegenerative condition in which mitochondrial fusion, fitness, and / or trafficking is / are impaired; a disease or disorder associated with mitofusin 1 (MFN1) or mitofusin 2 (MFN2) dysfunction; a disease associated with mitochondrial fragmentation, dysfunction, and / or dysmotility; a degenerative neuromuscular condition; Charcot-Marie-Tooth disease; Amyotrophic Lateral Sclerosis; Huntington's disease; Alzheimer's disease; Parkinson's disease; hereditary motor and sensory neuropathy; autism; autosomal dominant optic atrophy (ADOA); muscular dystrophy; Lou Gehrig's disease; cancer; mitochondrial myopathy; diabetes mellitus and deafness (DAD); Leber's hereditary optic neuropathy (LHON); Leigh syndrome; subacute sclerosing encephalopathy; neuropathy, ataxia, retinitis pigmentosa,Atty. Docket No.: 076760-000051 and ptosis (NARP); myoneurogenic gastrointestinal encephalopathy (MNGIE); myoclonic epilepsy with ragged red fibers (MERRF); mitochondrial myopathy, encephalomyopathy, lactic acidosis, and stroke-like symptoms (MELAS); mtDNA depletion; mitochondrial neurogastrointestinal encephalomyopathy (MNGIE); dysautonomic mitochondrial myopathy; mitochondrial channelopathy; pyruvate dehydrogenase complex deficiency (PDCD / PDH); diabetic neuropathy; chemotherapy-induced peripheral neuropathy; crush injury; spinal cord injury (SCI); traumatic brain injury; stroke; optic nerve injury; conditions that involve axonal disconnection; and any combination thereof.

[0066] Additional embodiments disclosed herein include:

[0067] Embodiment 1'. A composition comprising: a mitofusin activator having a structure represented by Formula 4A or Formula 4BFormula 4B or a pharmaceutically acceptable salt, solvate, hydrate, or tautomer thereof; wherein R1is an optionally substituted aryl or heteroaryl group, and aAtty. Docket No.: 076760-000051 mass ratio of the structure represented by Formula 4A to the structure represented by Formula 4B is about 60:40 or greater or about 40:60 or less.

[0068] Embodiment 2'. The composition of Embodiment 1', wherein R1is optionally substituted phenyl.

[0069] Embodiment 3'. The composition of Embodiment 1', wherein R1is phenyl.

[0070] Embodiment 4'. The composition of Embodiment 1', further comprising: a pharmaceutically acceptable excipient.

[0071] Embodiment 5'. The composition of Embodiment 1', wherein the mass ratio of the structure represented by Formula 4A to the structure represented by Formula 4B is about 95:5 or greater or about 5:95 or less.

[0072] Embodiment 6'. The composition of Embodiment 5', wherein R1is optionally substituted phenyl.

[0073] Embodiment 7'. The composition of Embodiment 5', wherein R1is phenyl.

[0074] Embodiment 8'. The composition of Embodiment 5', further comprising: a pharmaceutically acceptable excipient.

[0075] Embodiment 9'. The composition of Embodiment 5', wherein the mitofusin activator consists essentially of the structure represented by Formula 4A or the structure represented by Formula 4B.

[0076] Embodiment 10'. The composition of Embodiment 5', wherein the mitofusin activator consists essentially of the structure represented by Formula 4A.

[0077] Embodiment 11'. The composition of Embodiment 10', wherein R1is optionally substituted phenyl.

[0078] Embodiment 12'. The composition of Embodiment 10', wherein R1is phenyl.

[0079] Embodiment 13'. A method comprising: administering a therapeutically effective amount of the composition of Embodiment 1' to a subject having or suspected of having a mitochondria-associated disease, disorder, or condition.

[0080] Embodiment 14'. The method of Embodiment 13', wherein R1is optionally substituted phenyl.Atty. Docket No.: 076760-000051

[0081] Embodiment 15 . The method of Embodiment 13 , wherein R1is phenyl.

[0082] Embodiment 16'. The method of Embodiment 13', wherein the mass ratio of the structure represented by Formula 4A to the structure represented by Formula 4B is about 95:5 or greater or about 5:95 or less.

[0083] Embodiment 17'. The method of Embodiment 16', wherein R1is optionally substituted phenyl.

[0084] Embodiment 18'. The method of Embodiment 16', wherein R1is phenyl.

[0085] Embodiment 19'. The method of Embodiment 16', wherein the mitofusin activator consists essentially of the structure represented by Formula 4A or the structure represented by Formula 4B.

[0086] Embodiment 20'. The method of Embodiment 16', wherein the mitofusin activator consists essentially of the structure represented by Formula 4A.

[0087] Embodiment 21'. The method of Embodiment 20', wherein R1is optionally substituted phenyl.

[0088] Embodiment 22'. The method of Embodiment 20', wherein R1is phenyl.

[0089] Embodiment 23'. The method of any one of Embodiments 10'-22', wherein the mitochondria-associated disease, disorder or condition is a peripheral nervous system (PNS) or central nervous system (CNS) genetic or non-genetic disorder, physical damage, and / or chemical injury.

[0090] Embodiment 24'. The method of Embodiment 23', wherein the PNS or CNS disorder is one or more conditions selected from the group consisting of a chronic neurodegenerative condition in which mitochondrial fusion, fitness, and / or trafficking is / are impaired; a disease or disorder associated with mitofusin 1 (MFN1) or mitofusin 2 (MFN2) dysfunction; a disease associated with mitochondrial fragmentation, dysfunction, and / or dysmotility; a degenerative neuromuscular condition; Charcot-Marie-Tooth disease; Amyotrophic Lateral Sclerosis; Huntington's disease; Alzheimer's disease; Parkinson's disease; hereditary motor and sensory neuropathy; autism; autosomal dominant optic atrophy (ADOA); muscular dystrophy; LouAtty. Docket No.: 076760-000051Gehrig's disease; cancer; mitochondrial myopathy; diabetes mellitus and deafness (DAD); Leber's hereditary optic neuropathy (LHON); Leigh syndrome; subacute sclerosing encephalopathy; neuropathy, ataxia, retinitis pigmentosa, and ptosis (NARP); myoneurogenic gastrointestinal encephalopathy (MNGIE); myoclonic epilepsy with ragged red fibers (MERRF); mitochondrial myopathy, encephalomyopathy, lactic acidosis, and stroke-like symptoms (MELAS); mtDNA depletion; mitochondrial neurogastrointestinal encephalomyopathy (MNGIE); dysautonomic mitochondrial myopathy; mitochondrial channelopathy; pyruvate dehydrogenase complex deficiency (PDCD / PDH); diabetic neuropathy; chemotherapy-induced peripheral neuropathy; crush injury; spinal cord injury (SCI); traumatic brain injury; stroke; optic nerve injury; conditions that involve axonal disconnection; and any combination thereof.

[0091] Embodiment 25'. The method of any one of Embodiments 10'-22', wherein the mitochondria-associated disease, disorder or condition is age-induced sarcopenia or sarcopenia obesity.

[0092] Embodiment 26'. Use of the composition of any one of Embodiments 1-12 in the manufacture of a medicament for treating or preventing a disease, disorder, or condition to a subject in need thereof.

[0093] Embodiment 27'. The use of Embodiment 26', wherein the disease, disorder, or condition is associated with mitochondrial dysfunction.

[0094] Embodiment 28'. Use of the composition of any one of Embodiments 1-12 for activating mitofusin in a subject.

[0095] To facilitate a better understanding of the present disclosure, the following examples of preferred or representative embodiments are given. In no way should the following examples be read to limit, or to define, the scope of the invention.EXAMPLES

[0096] HPLC analyses were conducted with a Kinetex C18 column (4.6X50 mm, 5 pirn; Mobile phase A: 0.0375% TFA in water (v / v), B: 0.01875% TFA in Acetonitrile (v / v)) run at 50°C with absorbance at 200 nm.

[0097] LC-MS / MS (ESI) was performed using 2 systems: 1) SHIMADZU LC-MS-2020 with LabSolution V5.72 analysis software and a CHROMALITH@FLASH RP-18E 25*2.0 mm column run at 50°C with a PDA (220Atty. Docket No.: 076760-000051 and 254 nm) detector, acquired data in scan MS Mode (positive mode) with m / z=100-1000 scan range, drying gas (N2) flow: 15 L / min, DL voltage: 120V and Quarry DC voltage: 20V, or 2) Agilent 1200 / G6110A instrument with AgilentChemStation Rev. B. 04.03 software and an XBRIDGE C18 2.1*50 mm column run at 40°C with DAD (220 nm) / ELSD detector, acquired data in scan MS Mode (positive mode) with m / z=100-1000 scan range, drying gas (N2) flow: 10 L / min, 350°C, nebulizer pressure: 35 psi, capillary voltage: 2500V. NMR spectrometry was carried out on Brucker AVANCE NEO 400MHz with a 5 mm PABBO BB / 19F-1H / D Z-GRD probe.

[0098] Dose-response of mitofusin agonist fusogenicity was performed in Mfnl- or Mfn2-deficient MEFs (Mfnl-KO or Mfn2-KO MEFs) cultured at 37°C and 5% CO2-95% air. Cells were seeded on day 1 in 6 well plates at a density of 2xl04cells per well and compounds added at 9 concentrations (0.5 nM-10 pM dissolved in DMSO) overnight. Mitochondria were then stained with MitoTracker Orange (200 nM; M7510; Invitrogen, Carlsbad, CA, USA). Nuclei were stained with Hoescht (10 pg / ml; Invitrogen, Thermo Fisher Scientific Cat: # H3570). Images were acquired at room temperature on a Nikon Ti Confocal microscope using a 60 X 1.3 NA oilimmersion objective in Krebs-Henseleit buffer (138 NaCI, 3.7 nM KCI, 1.2 nM KH2PO4, 15 nM Glucose, 20 nM HEPES pH: 7.2-7.5, and 1 mM CaCI2). Laser excitation was 549 nm with emission at 590 nm for MitoTracker Orange and excitation at 306 nm with emission at 405 nm for Hoescht. Images were analyzed using ImageJ and fusogenecity quantified as mitochondrial aspect ratio (length / width), and were indexed to the maximal response elicited by the compound having a structure represented by Formula 1, a known mitofusin activator. Response curves were interpolated using the sigmoidal model using Prism 8 software. EC50 values are reported as mean with 95% confidence limits for at least 3 independent experiments.

[0099] Functional evaluation of mitofusin activation on mitochondrial depolarization was studied as follows. Cultured Mfn2-KO or Mfnl-KO MEFs were treated with DMSO or test compound (1 pM) for 24 hours, then were stained with tetramethylrhodamine ethyl ester (TMRE, Invitrogen), MitoTracker Green (Invitrogen), MitoTracker Orange (Invitrogen), or Hoechst (Invitrogen) for 30 min at 37°C in 5% CO2-95% air, washed twice in PBS. Images were acquiredAtty. Docket No.: 076760-000051 at room temperature on a Nikon Ti Confocal microscope using either 60 X 1.3 NA oil-immersion objective, in Krebs-Henseleit buffer (138 NaCI, 3.7 nM KCI, 1.2 nM KH2PO4, 15 nM glucose, 20 nM HEPES, pH: 7.2-7.5, and 1 mM CaCI2): laser excitation was 488 nm with emission at 510 nm for MitoTracker Green, 549 nm with emission at 590 nm for TMRE, and 306 nm with emission 405 nm for Hoecsht. Mitochondrial depolarization was reported as % number of green mitochondria / number of yellow+green mitochondria using Image J.

[0100] In vitro pharmacokinetic analyses were performed in duplicate using standard methods by WuXi AppTec Co. Ltd. (Shanghai, China). Plasma protein binding was measured by equilibrium dialysis; % bound = (l-[free compound in dialysate] / [total compound in retentate]) x 100. Plasma stability of 2 uM compounds in clarified freeze-thawed plasma was assessed by LC- MS / MS of supernatants after protein precipitation; 120 min data are reported for studies including 0, 10, 30, 60, and 120 min. Liver microsome stability of 1 uM compounds in liver microsomes (0.5 mg / ml) after 0, 5, 10, 20, 30, 60 min. incubation was assessed by LC / MS / MS of reaction extracts.[O1O1] Passive artificial blood brain barrier membrane permeability assay (PAMPA-BBB) were performed using 150 pL of 10 pM compounds (5% DMSO) added to PVDF membranes pre-coated with 5 pL of 1% brain polar lipid extract (Porcine) / dodecane mixture and incubated for 4 h at room temperature with shaking at 300 rpm. Donor and acceptor samples were analyzed by LC- MS / MS.

[0102] Further testing details for the Mfn activity and PAMPA are provided in U.S. Patents Applications 11,026,904 and 11,083,699, which are incorporated by reference herein.

[0103] Synthesis of the Mitofusin Activator having Formula 1. This mitofusin activator was prepared as described in U.S. Patent 11,083,699, which is incorporated herein by reference.

[0104] Racemic Synthesis of the Mitofusin Activator having Formula 4 (R1= phenyl). The mitofusin activator having Formula 4 (R1= phenyl) was synthesized as outlined in FIG. 1. Synthetic details are similar to those described for Formula 30 in U.S. Patent Application Publication 2024 / 0050386, which is incorporated herein by reference in its entirety. A mixture of (R,R) and (S,S) stereoisomers was produced by theAtty. Docket No.: 076760-000051 cyclopropanation chemistry.XH NMR: (400 MHz, DMSO-c / e) 6 7.69 (d, J = 4.4 Hz, 1H), 7.27 - 7.24 (m, 2H), 7.18 - 7.13 (m, 3H), 4.51 (d, J = 4.4 Hz, 1H), 3.30 - 3.26 (m, 1H), 2.57 - 2.53 (m, 2H), 2.32 - 2.31 (m, 1H), 1.89 - 1.80 (m, 3H), 1.63 - 1.57 (m, 4H), 1.37 - 1.31 (m, 6H), 1.08 - 1.04 (m, 2H), 0.70 - 0.68 (m, 1H), 0.48-0.46 (dt, J = 8.8, 4.8 Hz, 1H), 0.37 - 0.36 (m, 1H). LCMS m / z = 316.2 (M + H)+. HPLC: RT = 2.738 mins, 96.2% purity at 220 nm and 98.5% at 254 nm.

[0105] Supercritical fluid chromatography (SFC) was employed to separate the (R,R) and (S,S) stereoisomers produced from the racemic synthesis. Two peaks were observed (FIG. 2) in approximately a 1 : 1 area ratio, the faster-eluting peak of which was designated as Pl and the slower- eluting peak of which was designated as P2.

[0106] Subsequent resyntheses of the (R,R) and (S,S) stereoisomers of Formula 4 (R1= phenyl) were performed via an alternative synthetic route (6 total steps) capable of definitively setting the cyclopropane ring stereochemistry as a single stereoisomer. Specifically, the (R,R) stereoisomer was synthesized starting from (S)-epichlorohydrin, and the (S,S) stereoisomer was synthesized starting from (R)-epichlorohydrin. In brief, the desired epichlorohydrin enantiomer was reacted with (3-phenylpropyl)magnesium bromide, followed by reclosure of the epoxide ring and subsequent conversion of the epoxide ring to the corresponding cyclopropane ring via a modified Horner-Wadsworth-Emmons reaction with triethylphosphonoacetate. The resulting cyclopropanecarboxylate was decarboxylated into the corresponding BOC-protected cyclopropaneamine. Following removal of the BOC protecting group, the cyclopropaneamine was coupled with (lr,4r)-4- hydroxycyclohexane-1 -carboxylic acid to form the specified stereoisomer of the mitofusin activator.

[0107] HPLC elution times of the resynthesized (R,R) and (S,S) stereoisomers were then compared against the elution times of the racemic mixture. The (R,R)-stereoisomer had an elution time matching that of P2, and the (S,S)-stereoisomer had an elution time matching that of Pl. Accordingly, P2 has a structure represented by Formula 5A, and Pl has a structure represented by Formula 5B. P2 was produced in an anhydrous rod-like crystalAtty. Docket No.: 076760-000051 morphology and had a melting point of approximately 162°C, as determined by thermogravimetic analysis (TGA).Formula 5A

[0108] Pharmacokinetic Data and Biological Efficacy. FIG. 3 is a dose-response curve for Pl and P2. As shown, P2 promoted essentially full MFN activation (EC5o = 623 pM) in vitro, whereas Pl failed to reach a 50% response at the highest tested dose (ECso > 1 ^m). A 1 piM solution of the mitofusin activator of Formula 1 was used to establish 100% fusogenecity in FIG. 3. Additional testing data is summarized in Table 1.Table 1Atty. Docket No.: 076760-000051As shown, the mitofusin activators having Formulas 1, 2A, and 4 (mixture of stereoisomers, R1= phenyl) exhibited similar ECso values toward mitofusin activation. The values for the mitofusin activator having Formula 4 represent the weighted average of the mixture of Pl and P2. Surprisingly, the PAMPA assay of the mitofusin activator having Formula 4 exhibited over twice the value of that is Formula 2A, which is characteristic of greater passive bloodbrain barrier permeability. Additionally, the mitofusin activator having Formula 4 exhibited a longer plasma half-life when administered orally and a much higher brain: plasma ratio. The plasma levels of P2 exhibited phasic increases when administered orally, which is suggestive of enterohepatic recirculation (EHR) in vivo. EHR is believed to result from glucuronidation and may contribute to the longer in vivo half-life of P2 and similar compounds in comparison to previous classes of mitofusin activators.

[0109] P2 was also tested in worm and mouse models to examine the effect of mitofusin activation in age-related sarcopenia.

[0110] Administration of P2 to age-synchronized worms (C. eiegans increased survival (longevity) in a dose-dependent manner. Surprisingly, extended survival was observed when P2 administration began on day 5 of the study instead of upon day 1. Worms subjected to thermal or oxidative stress also exhibited increased survival times when dosed with P2.

[0111] In the corresponding mouse study, eighty-week old "aged" mice were dosed with P2 and compared against twelve-week old "young" controls. Mice treated with P2 exhibited increased exercise capacity, muscle strength, and neuromuscular integrity.

[0112] The effect of P2 administration for treatment of metabolic dysfunction in the aged mice was also examined. Prior to P2 administration, the aged mice had increased total fat and increased saturated fat content compared to the young mice controls. Following administration of P2, totalAtty. Docket No.: 076760-000051 body fat content decreased by about 25%, most of which was attributable to reduction of saturated fat in the test group.

[0113] Unless indicated to the contrary, the numerical parameters set forth in the following specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained by the embodiments of the present invention. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claim, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques.

[0114] One or more illustrative embodiments incorporating various features are presented herein. Not all features of a physical implementation are described or shown in this application for the sake of clarity. It is understood that in the development of a physical embodiment incorporating the embodiments of the present invention, numerous implementation-specific decisions must be made to achieve the developer's goals, such as compliance with system-related, business-related, government-related and other constraints, which vary by implementation and from time to time. While a developer's efforts might be time-consuming, such efforts would be, nevertheless, a routine undertaking for those of ordinary skill in the art and having benefit of this disclosure.

[0115] While various systems, tools and methods are described herein in terms of "comprising" various components or steps, the systems, tools and methods can also "consist essentially of" or "consist of" the various components and steps.

[0116] As used herein, the phrase "at least one of" preceding a series of items, with the terms "and" or "or" to separate any of the items, modifies the list as a whole, rather than each member of the list (i.e., each item). The phrase "at least one of" allows a meaning that includes at least one of any one of the items, and / or at least one of any combination of the items, and / or at least one of each of the items. By way of example, the phrases "at least one of A, B, and C" or "at least one of A, B, or C" each refer to only A, only B, or only C; any combination of A, B, and C; and / or at least one of each of A, B, and C.Atty. Docket No.: 076760-000051

[0117] Therefore, the disclosed systems, tools and methods are well adapted to attain the ends and advantages mentioned as well as those that are inherent therein. The particular embodiments disclosed above are illustrative only, as the teachings of the present disclosure may be modified and practiced in different but equivalent manners apparent to those skilled in the art having the benefit of the teachings herein. Furthermore, no limitations are intended to the details of construction or design herein shown, other than as described in the claims below. It is therefore evident that the particular illustrative embodiments disclosed above may be altered, combined, or modified and all such variations are considered within the scope of the present disclosure. The systems, tools and methods illustratively disclosed herein may suitably be practiced in the absence of any element that is not specifically disclosed herein and / or any optional element disclosed herein. While systems, tools and methods are described in terms of "comprising," "containing," or "including" various components or steps, the systems, tools and methods can also "consist essentially of" or "consist of" the various components and steps. All numbers and ranges disclosed above may vary by some amount. Whenever a numerical range with a lower limit and an upper limit is disclosed, any number and any included range falling within the range is specifically disclosed. In particular, every range of values (of the form, "from about a to about b," or, equivalently, "from approximately a to b," or, equivalently, "from approximately a-b") disclosed herein is to be understood to set forth every number and range encompassed within the broader range of values. Also, the terms in the claims have their plain, ordinary meaning unless otherwise explicitly and clearly defined by the patentee. Moreover, the indefinite articles "a" or "an," as used in the claims, are defined herein to mean one or more than one of the elements that it introduces. If there is any conflict in the usages of a word or term in this specification and one or more patent or other documents that may be incorporated herein by reference, the definitions that are consistent with this specification should be adopted.

Claims

Atty. Docket No.: 076760-000051CLAIMSWhat is claimed is the following:

1. A composition comprising: a mitofusin activator having a structure represented by Formula4A or Formula 4BFormula 4B or a pharmaceutically acceptable salt, solvate, hydrate, or tautomer thereof; wherein R1is an optionally substituted aryl or heteroaryl group, and a mass ratio of the structure represented by Formula 4A to the structure represented by Formula 4B is about 60:40 or greater or about 40:60 or less.

2. The composition of claim 1, wherein R1is optionally substituted phenyl.Atty. Docket No.: 076760-0000513. The composition of claim 1, wherein R1is phenyl.

4. The composition of claim 1, further comprising: a pharmaceutically acceptable excipient.

5. The composition of claim 1, wherein the mass ratio of the structure represented by Formula 4A to the structure represented by Formula 4B is about 95:5 or greater or about 5:95 or less.

6. The composition of claim 5, wherein R1is optionally substituted phenyl.

7. The composition of claim 5, wherein R1is phenyl.

8. The composition of claim 5, further comprising: a pharmaceutically acceptable excipient.

9. The composition of claim 5, wherein the mitofusin activator consists essentially of the structure represented by Formula 4A or the structure represented by Formula 4B.

10. The composition of claim 5, wherein the mitofusin activator consists essentially of the structure represented by Formula 4A.

11. The composition of claim 10, wherein R1is optionally substituted phenyl.

12. The composition of claim 10, wherein R1is phenyl.

13. A method comprising: administering a therapeutically effective amount of the composition of claim 1 to a subject having or suspected of having a mitochondria-associated disease, disorder, or condition.

14. The method of claim 13, wherein R1is optionally substituted phenyl.Atty. Docket No.: 076760-00005115. The method of claim 13, wherein R1is phenyl.

16. The method of claim 13, wherein the mass ratio of the structure represented by Formula 4A to the structure represented by Formula 4B is about 95:5 or greater or about 5:95 or less.

17. The method of claim 16, wherein R1is optionally substituted phenyl.

18. The method of claim 16, wherein R1is phenyl.

19. The method of claim 16, wherein the mitofusin activator consists essentially of the structure represented by Formula 4A or the structure represented by Formula 4B.

20. The method of claim 16, wherein the mitofusin activator consists essentially of the structure represented by Formula 4A.

21. The method of claim 20, wherein R1is optionally substituted phenyl.

22. The method of claim 20, wherein R1is phenyl.

23. The method of any one of claims 10-22, wherein the mitochondria- associated disease, disorder or condition is a peripheral nervous system (PNS) or central nervous system (CNS) genetic or non-genetic disorder, physical damage, and / or chemical injury.

24. The method of claim 23, wherein the PNS or CNS disorder is one or more conditions selected from the group consisting of a chronic neurodegenerative condition in which mitochondrial fusion, fitness, and / or trafficking is / are impaired; a disease or disorder associated with mitofusin 1 (MFN1) or mitofusin 2 (MFN2) dysfunction; a disease associated with mitochondrial fragmentation, dysfunction, and / or dysmotility; a degenerative neuromuscular condition; Charcot-Marie- Tooth disease; Amyotrophic Lateral Sclerosis; Huntington's disease; Alzheimer's disease; Parkinson's disease; hereditary motor andAtty. Docket No.: 076760-000051 sensory neuropathy; autism; autosomal dominant optic atrophy (ADOA); muscular dystrophy; Lou Gehrig's disease; cancer; mitochondrial myopathy; diabetes mellitus and deafness (DAD); Leber's hereditary optic neuropathy (LHON); Leigh syndrome; subacute sclerosing encephalopathy; neuropathy, ataxia, retinitis pigmentosa, and ptosis (NARP); myoneurogenic gastrointestinal encephalopathy (MNGIE); myoclonic epilepsy with ragged red fibers (MERRF); mitochondrial myopathy, encephalomyopathy, lactic acidosis, and stroke-like symptoms (MELAS); mtDNA depletion; mitochondrial neurogastrointestinal encephalomyopathy (MNGIE); dysautonomic mitochondrial myopathy; mitochondrial channelopathy; pyruvate dehydrogenase complex deficiency (PDCD / PDH); diabetic neuropathy; chemotherapy-induced peripheral neuropathy; crush injury; spinal cord injury (SCI); traumatic brain injury; stroke; optic nerve injury; conditions that involve axonal disconnection; and any combination thereof.

25. The method of any one of claims 10-22, wherein the mitochondria- associated disease, disorder or condition is age-induced sarcopenia or sarcopenia obesity.

26. Use of the composition of any one of claims 1-12 in the manufacture of a medicament for treating or preventing a disease, disorder, or condition to a subject in need thereof.

27. The use of claim 26, wherein the disease, disorder, or condition is associated with mitochondrial dysfunction.

28. Use of the composition of any one of claims 1-12 for activating mitofusin in a subject.

Citation Information

Patent Citations

  • Mitofusin activators having an endocyclic-bonded carbonyl group and methods for use thereof

    US20240050386A1

  • Mitofusin modulation agents and methods of use thereof

    WO2019094830A1